ASK1 Inhibition Halts Disease Progression in Preclinical Models of Pulmonary Arterial Hypertension
Grant R. Budas(Gilead Sciences (United States)), Ralph T. Schermuly(Justus-Liebig-Universität Gießen), Tatyana Novoyatleva(Justus-Liebig-Universität Gießen), Ford Hinojosa-Kirschenbaum(Gilead Sciences (United States)), Gayathri Viswanathan(Duke University), Tian Xia(University of Vienna), Swathi Veeroju(German Center for Lung Research), Norbert Weißmann(Cardio-Pulmonary Institute), Hossein Ardeschir Ghofrani(Justus-Liebig-Universität Gießen), Friedrich Grimminger(Justus-Liebig-Universität Gießen), Mario Boehm(German Center for Lung Research), Werner Seeger(Justus-Liebig-Universität Gießen), John T. Liles(Gilead Sciences (United States)), Baktybek Kojonazarov(Cardio-Pulmonary Institute)
American Journal of Respiratory and Critical Care Medicine
September 14, 2017
Cited by 100
Related Papers
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k
Clinical classification of pulmonary hypertension
|Journal of the American College of Cardiology|2004|1.9k
Inhaled Iloprost for Severe Pulmonary Hypertension
|New England Journal of Medicine|2002|1.8k
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
|New England Journal of Medicine|2013|1.4k
Reversal of experimental pulmonary hypertension by PDGF inhibition
|Journal of Clinical Investigation|2005|1.1k